


# VALUE OF MEDICINES IN CANADA

WORKING TOGETHER FOR A SUSTAINABLE HEALTHCARE SYSTEM



Innovative medicines make up just **6.4%** of healthcare spending

...AND GROWTH HAS BEEN MUCH LESS THAN OTHER PARTS OF THE HEALTHCARE SYSTEM



## CANADA'S CURRENT PRICING POLICIES ENSURE VALUE-PRICED MEDICINES



### Patented Medicine Prices Review Board

Ensures prices are non-excessive based on international prices and comparable drugs in Canada



### pan-Canadian Pharmaceutical Alliance

Ensures affordability by leveraging the buying power of the public drug plans



### Health Technology Assessments

Ensures value-based formulary listings based on comparative clinical benefit and cost




### Private Insurance

Ensures affordability to employers through negotiation and other tools


## CANADIAN PRICES ARE THE 3<sup>RD</sup> LOWEST FOR INNOVATIVE SINGLE-SOURCE PRODUCTS

Represents 672 single-source medicines (≈80% of total) reported to PMPRB




## PATENTED MEDICINES PRICE INDEX SHOWS LOW TO NO GROWTH


(1988-2014)




# INNOVATIVE MEDICINES HAVE DELIVERED EXTRAORDINARY VALUE FOR PATIENTS...




73% of increase in life expectancy between 2000 – 2009 was due to new medicines




2 of 3 people diagnosed with cancer today survive 5 years, compared to 1 in 3 in 1964




A 20-year-old diagnosed with HIV today can expect to live into his or her 70's



Hepatitis C is curable




Using long acting injectable therapies for schizophrenia:  
 – saves \$17,300/patient/year  
 – 32 fewer hospital days  
 – 6X fewer ER visits



Overall survival has increased 32% for patients treated for Multiple Myeloma – from 2000 to 2010

## ..AND VALUE FOR THE HEALTHCARE SYSTEM



Globally, for every \$1 spent on innovative medicines, non-medicine spending drops by \$7



Janssen has committed \$1 billion in Life Sciences investments (since 2014)



Provides medicines to patients for compassionate use



Helps 45,000 patients through the BioAdvance® Patient Support Program



Has 649 clinical trial sites across Canada involving >11,000 patients

## JANSSEN BELIEVES COLLABORATION WILL LEAD TO A SUSTAINABLE VISION FOR HEALTHCARE IN CANADA



All stakeholders should be part of shaping healthcare policy. By working together with government and policy makers, we can help ensure sustainable healthcare for Canadians.

Contact us at: [collaboration@its.jnj.com](mailto:collaboration@its.jnj.com)